Medical Devices

Request for TOC Request for Sample
BUY NOW

Europe Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Medical Devices | Published Report | Mar 2021 | Europe | 350 Pages | No of Tables: 193 | No of Figures: 55

Report Description

Europe Prostate Cancer Diagnostics Drug Market, By Product Type (Instruments, Reagents & Consumables and Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer and Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic), Sample Type (Blood, Tissue, Urine and Others), End Users (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Belgium and Rest of Europe) Industry Trends and Forecast to 2028

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Europe Prostate Cancer Diagnostics Market

Prostate cancer diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.5% in the forecast period of 2021 to 2028 and is expected to reach USD 1,604.78 million by 2028 from USD 636.30 million in 2020. Increasing focus on the disease burden and increasing awareness regarding the disease are the major drivers which are propelling the market in the forecast period.

Instruments, reagents & consumables and accessories are used for the diagnosis. The PSA testing, digital rectal exams, MRI, PET/CT scan among others are some preliminary and confirmatory tests used in the diagnosis of prostate cancer. The increasing prevalence of prostate cancer, increased research & development in prostate cancer diagnostics, increase in geriatric population, launch of new products for prostate cancer diagnostics are expected to drive the prostate cancer diagnostics market growth. Moreover, rising investment and funding by emerging players, reimbursement policy for prostate cancer diagnostics and government initiatives towards cancer diagnostics bolsters the prostate cancer diagnostics market growth.

The demand for prostate cancer diagnostics has increased in both developed as well as in developing countries and the reason behind this is the increasing focus on mortality of prostate cancer. The prostate cancer diagnostics market is growing due to introduction of innovative products, increasing awareness and various government initiatives. The market will grow in the forecasted period due to exploration of emerging markets, strategic initiatives by market players and increasing awareness regarding hair problems.

The prostate cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Europe Prostate Cancer Diagnostics Market Scope and Market Size

The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.

  • On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories. In 2021, reagents & consumables segment is dominating in the prostate cancer diagnostics market as it includes the PSA testing products which is the primary test recommended for preliminary testing. PSA measures protein made by cells in prostate gland which is the first line of diagnosis for prostate cancer.
  • On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests. In 2021, preliminary screening tests segment is dominating in the prostate cancer diagnostics market as the number of preliminary tests surpass the number of confirmatory tests by significant percentage.
  • On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics. In 2021, geriatrics segment is dominating in the prostate cancer diagnostics market as around 60% of cases are diagnosed in men over 65 year of age. The average age of prostate cancer diagnostics is 66 years. The disease rarely occurs in those younger than 40. The number of new cases diagnosed in black men is 60% higher than to the number of new cases diagnosed in white men.
  • On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others. In 2021, prostatic adenocarcinoma segment dominates the prostate cancer diagnostics market because more than 95 percent of prostate cancers are adenocarcinomas which develop in the gland cells and line of the prostate gland. Nearly, all the men with prostate cancer have this type. It is the second leading cause of cancer-related death in men. Once the cancer reaches a certain stage, then the abnormal cells spread to other parts of the body, hence causing metastasis which leads to dominating the segment of the market.
  • On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III. Most of the men diagnosed and treated at the local or regional stages will be disease-free after five years. This type of cancer does not spread in any of the nearby tissues or to distant parts of the body. The stages present in localized prostate cancer are stage 1 and 2. The growth of tumor in low-risk localized prostate cancer is slow.
  • On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.
  • On the basis of end user, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, Independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as this segment is specialized in conducting various prostate cancer diagnostics. Moreover, independent diagnostic laboratories enable the facilitation of robust, on-time, cost-effective and high quality diagnostic care and services in safe healthcare environment and are convenient for consulting physician/healthcare institution to outsource bulk diagnostics tests to independent diagnostic laboratories for better customer services.
  • On the basis of distribution type, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs. With the increasing cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers.

Prostate Cancer Diagnostics Market Country Level Analysis

The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.

The countries covered in the prostate cancer diagnostics market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Belgium and Rest of Europe.

Europe is expected to grow with the highest CAGR in the forecasted period as in the growing prevalence of prostate cancer and favorable reimbursement landscape. Germany is expected to dominate in the Europe market primarily due to increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market 

Prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis

Prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market.

The major companies providing prostate cancer diagnostics are F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, OPKO Health Inc., Abott, Beckman Coulter, Inc. (A Subsidiary of Danaher), among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the prostate cancer diagnostics market.

For instance,  

  • In December 2020, Fujirebio Europe announced they have been granted with a sum amount of USD 876 thousand from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies. This is for developing cost efficient, accurate and portable IVD. This will enhance the company profile and will increase the research and development of the company.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the prostate cancer diagnostics market which also provides the benefit for organisation to improve their offering for prostate cancer diagnostics market.

 

 


SKU-

Table of Content

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. product type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. MARKET end users coverage GRID
    11. vendor share analysis
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. Epidemiology
  5. COMPARATIVE ANALYSIS WITH PARENT MARKET
  6. REGULATORY FRAMEWORK: EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
    1. REGULATORY SCENARIO IN EUROPEAN UNION
  7. market overview
    1. drivers
      1. INCREASING PREVALENCE OF PROSTATE CANCER
      2. INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
      3. INCREASE IN GERIATRIC POPULATION
      4. LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
      5. DISEASE CAUSING PROSTATE CANCER
    2. RESTRAINTS
      1. CONTROVERSY RELATED TO PSA TESTING
      2. HIGH COST OF DIAGNOSTICS PROCEDURE
      3. LACK OF SKILLED AND CERTIFIED PROFESSIONALS
    3. OPPORTUNITIES
      1. RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
      2. REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
      3. GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
      4. RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
    4. Challenges
      1. STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
      2. OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
      3. INACCURATE DIAGNOSIS RESULTS
  8. IMPACT OF COVID-19 ON EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
    5. KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
    6. CONCLUSION
  9. Europe prostate cancer diagnostics market, BY product type
    1. overview
    2. reagents & consumables
    3. instruments
    4. accessories
  10. Europe prostate cancer diagnostics market, BY DIAGNOSTICS TYPE
    1. overview
    2. preliminary screening tests
      1. Prostate-Specific Antigen (PSA) Test
      2. Digital Rectal Exam (DRE) Test
    3. Confirmatory Tests
      1. PCA3 Test
      2. biopsy
      3. imaging tests
        1. ULTRASOUND
        2. MAGNETIC RESONANCE IMAGING (MRI)
          1. MULTIPARAMETRIC MRI
          2. MRI FUSION-GUIDED PROSTATE BIOPSY
        3. CT SCAN
        4. BONE SCAN
        5. PET/CT SCAN
      4. biomarker
        1. RNA BIOMARKERS
        2. DNA BIOMARKERS
        3. PROTEIN BIOMARKERS
  11. Europe prostate cancer diagnostics market, By type
    1. overview
    2. PROSTATIC ADENOCARCINOMA
    3. small cell carcinoma
    4. Others
  12. Europe prostate cancer diagnostics market, BY AGE GROUP
    1. overview
    2. geriatrics
    3. adult
    4. Pediatric
  13. Europe prostate cancer diagnostics market, BY Stage
    1. overview
    2. LOCALIZED PROSTATE CANCER
    3. RECURRENT/ADVANCED PROSTATE CANCER
    4. CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
  14. Europe prostate cancer diagnostics market, BY sample type
    1. overview
    2. Blood
    3. tissue
    4. urine
    5. others
  15. Europe prostate cancer diagnostics market, BY end users
    1. overview
    2. Independent Diagnostic Laboratories
    3. hospitals
    4. Clinics
    5. Ambulatory Surgical Centers
    6. Cancer Research Institutes
    7. others
  16. Europe prostate cancer diagnostics market, BY Distribution Channel
    1. overview
    2. direct tender
    3. retail sales
  17. Europe prostate cancer diagnostics market, BY Country
    1. GERMANY
    2. FRANCE
    3. u.k.
    4. iTALY
    5. SPAIN
    6. RUSSIA
    7. SWITZERLAND
    8. NETHERLANDS
    9. TURKEY
    10. bELGIUM
    11. REST OF EUROPE
  18. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY landscape
    1. company share analysis: europe
  19. SWOT
  20. company profile
    1. F. Hoffmann-La Roche Ltd
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfoli0
      4. RECENT DEVELOPMENTs
    2. Abbott
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    3. siemens HEALTHCARE gmbh
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. OPko HEALTH INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. Beckman Coulter, Inc. (A Subsidiary of Danaher)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. acon laboratories inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    7. Biomerieux sa
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    8. Diasorin s.p.a
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLI0
      4. RECENT DEVELOPMENTS
    9. Eurolyser Diagnostica GmbH
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    10. FUJIREBIO
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLI
      3. RECENT DEVELOPMENTS
    11. GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. HOLOGIC, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. MDXHEALTHCARE
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    14. Myraid genetics, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    15. Prostatype Genomics
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    16. PROTEOMEDIX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  21. questionnaire
  22. related reports

List of Table

TABLE 1 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER

TABLE 2 Europe prostate cancer diagnostics market, By product type, 2019-2028 (USD Million)

TABLE 3 Europe prostate cancer diagnostics market, By product type, 2019-2028 (UNits)

TABLE 4 Europe prostate cancer diagnostics market, By DIAGNOSTICS TYPE, 2019-2028 (USD Million)

TABLE 5 EUROPE preliminary screening tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 6 EUROPE Confirmatory tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 7 EUROPE imaging tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 8 EUROPE Magnetic Resonance Imaging (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 9 EUROPE biomarker IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 10 Europe prostate cancer diagnostics market, By type, 2019-2028 (USD million)

TABLE 11 Europe prostate cancer diagnostics market, By age group, 2019-2028 (USD Million)

TABLE 12 Europe prostate cancer diagnostics market, By Stage, 2019-2028 (USD Million)

TABLE 13 Europe prostate cancer diagnostics market, By Sample Type, 2019-2028 (USD Million)

TABLE 14 Europe prostate cancer diagnostics market, By End Users, 2019-2028 (USD Million)

TABLE 15 Europe prostate cancer diagnostics market, By distribution channel, 2019-2028 (USD Million)

TABLE 16 Europe prostate cancer diagnostics market, By country, 2019-2028 (USD Million)

TABLE 17 GERMANY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 18 GERMANY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 19 GERMANY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 20 GERMANY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 21 GERMANY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 22 GERMANY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 23 GERMANY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 24 GERMANY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 25 GERMANY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 26 GERMANY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 27 GERMANY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 28 GERMANY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 29 GERMANY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 30 GERMANY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 31 FRANCE Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 32 FRANCE Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 33 FRANCE Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 34 FRANCE Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 35 FRANCE Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 36 FRANCE Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 37 FRANCE Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 38 FRANCE Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 39 FRANCE Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 40 FRANCE Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 41 FRANCE Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 42 FRANCE Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 43 FRANCE Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 44 FRANCE Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 45 U.K. Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 46 U.K. Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 47 U.K. Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 48 U.K. Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 49 U.K. Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 50 U.K. Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 51 U.K. Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 52 U.K. Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 53 U.K. Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 54 U.K. Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 55 U.K. Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 56 U.K. Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 57 U.K. Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 58 U.K. Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 59 ITALY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 60 ITALY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 61 ITALY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 62 ITALY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 63 ITALY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 64 ITALY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 65 ITALY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 66 ITALY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 67 ITALY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 68 ITALY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 69 ITALY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 70 ITALY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 71 ITALY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 72 ITALY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 73 SPAIN Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 74 SPAIN Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 75 SPAIN Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 76 SPAIN Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 77 SPAIN Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 78 SPAIN Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 79 SPAIN Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 80 SPAIN Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 81 SPAIN Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 82 SPAIN Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 83 SPAIN Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 84 SPAIN Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 85 SPAIN Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 86 SPAIN Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 87 RUSSIA Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 88 RUSSIA Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 89 RUSSIA Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 90 RUSSIA Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 91 RUSSIA Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 92 RUSSIA Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 93 RUSSIA Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 94 RUSSIA Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 95 RUSSIA Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 96 RUSSIA Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 97 RUSSIA Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 98 RUSSIA Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 99 RUSSIA Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 100 RUSSIA Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 101 SWITZERLAND Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 102 SWITZERLAND Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 103 SWITZERLAND Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 104 SWITZERLAND Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 105 SWITZERLAND Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 106 SWITZERLAND Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 107 SWITZERLAND Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 108 SWITZERLAND Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 109 SWITZERLAND Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 110 SWITZERLAND Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 111 SWITZERLAND Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 112 SWITZERLAND Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 113 SWITZERLAND Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 114 SWITZERLAND Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 115 NETHERLANDS Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 116 NETHERLANDS Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 117 NETHERLANDS Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 118 NETHERLANDS Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 119 NETHERLANDS Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 120 NETHERLANDS Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 121 NETHERLANDS Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 122 NETHERLANDS Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 123 NETHERLANDS Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 124 NETHERLANDS Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 125 NETHERLANDS Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 126 NETHERLANDS Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 127 NETHERLANDS Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 128 NETHERLANDS Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 129 TURKEY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 130 TURKEY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 131 TURKEY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 132 TURKEY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 133 TURKEY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 134 TURKEY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 135 TURKEY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 136 TURKEY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 137 TURKEY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 138 TURKEY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 139 TURKEY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 140 TURKEY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 141 TURKEY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 142 TURKEY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 143 BELGIUM Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 144 BELGIUM Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 145 BELGIUM Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 146 BELGIUM Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 147 BELGIUM Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 148 BELGIUM Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 149 BELGIUM Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 150 BELGIUM Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 151 BELGIUM Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 152 BELGIUM Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 153 BELGIUM Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 154 BELGIUM Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 155 BELGIUM Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 156 BELGIUM Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 157 rest of Europe prostate cancer diagnostics market, By Product Type, 2019-2028 (USD Million)

List of Figure

FIGURE 1 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: segmentation

FIGURE 2 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: data triangulation

FIGURE 3 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: regional VS country MARKET ANALYSIS

FIGURE 5 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MARKET end users coverage GRID

FIGURE 10 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER and INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICs are DRIVing THE EUROPE PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 REAGENTS & CONSUMABLES segment is expected to account for the largest share of the EUROPE PROSTATE CANCER DIAGNOSTICS MARKETin 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PROSTATE CANCER DIAGNOSTICS MARKET

FIGURE 15 GERIATRIC POPULATION IN THE EUROPEAN REGION

FIGURE 16 Europe prostate cancer diagnostics market : BY product type, 2020

FIGURE 17 Europe prostate cancer diagnostics market : BY product type, 2021-2028 (USD Million)

FIGURE 18 Europe prostate cancer diagnostics market : BY product type, CAGR (2021-2028)

FIGURE 19 PROSTATE CANCER DIAGNOSTICS market : BY product type, LIFELINE CURVE

FIGURE 20 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, 2020

FIGURE 21 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE 2021-2028 (USD Million)

FIGURE 22 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, CAGR (2021-2028)

FIGURE 23 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, LIFELINE CURVE

FIGURE 24 Europe prostate cancer diagnostics market : By type, 2020

FIGURE 25 Europe prostate cancer diagnostics market : By type, 2021-2028 (USD Million)

FIGURE 26 Europe prostate cancer diagnostics market : By type, CAGR (2021-2028)

FIGURE 27 Europe prostate cancer diagnostics market : By type, LIFELINE CURVE

FIGURE 28 Europe prostate cancer diagnostics market : BY age group, 2020

FIGURE 29 Europe prostate cancer diagnostics market : BY age group, 2021-2028 (USD Million)

FIGURE 30 Europe prostate cancer diagnostics market : BY age group, CAGR (2021-2028)

FIGURE 31 Europe prostate cancer diagnostics market : BY age group, LIFELINE CURVE

FIGURE 32 Europe prostate cancer diagnostics market : BY stage, 2020

FIGURE 33 Europe prostate cancer diagnostics market : BY stage, 2021-2028 (USD Million)

FIGURE 34 Europe prostate cancer diagnostics market : BY stage, CAGR (2021-2028)

FIGURE 35 Europe prostate cancer diagnostics market : BY stage, LIFELINE CURVE

FIGURE 36 Europe prostate cancer diagnostics market : BY sample type, 2020

FIGURE 37 Europe prostate cancer diagnostics market : BY sample type, 2021-2028 (USD Million)

FIGURE 38 Europe prostate cancer diagnostics market : BY sample type, CAGR (2021-2028)

FIGURE 39 Europe prostate cancer diagnostics market : BY sample type, LIFELINE CURVE

FIGURE 40 Europe prostate cancer diagnostics market : BY end users, 2020

FIGURE 41 Europe prostate cancer diagnostics market : BY end users, 2021-2028 (USD Million)

FIGURE 42 Europe prostate cancer diagnostics market : BY end users, CAGR (2021-2028)

FIGURE 43 Europe prostate cancer diagnostics market : BY end users, LIFELINE CURVE

FIGURE 44 Europe prostate cancer diagnostics market : BY distribution channel, 2020

FIGURE 45 Europe prostate cancer diagnostics market : BY distribution channel, 2021-2028 (USD Million)

FIGURE 46 Europe prostate cancer diagnostics market : BY distribution channel, CAGR (2021-2028)

FIGURE 47 Europe prostate cancer diagnostics market : BY distribution, LIFELINE CURVE

FIGURE 48 Europe prostate cancer diagnostics market : SNAPSHOT (2020)

FIGURE 49 Europe prostate cancer diagnostics market : BY COUNTRY (2020)

FIGURE 50 Europe prostate cancer diagnostics market : BY COUNTRY (2021 & 2028)

FIGURE 51 Europe prostate cancer diagnostics market : BY COUNTRY (2020 & 2028)

FIGURE 52 Europe prostate cancer diagnostics market : BY Product type (2021-2028)

FIGURE 53 europe Prostate cancer diagnostics market: company share 2020 (%)

View Infographics

FIGURE 1 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: segmentation

FIGURE 2 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: data triangulation

FIGURE 3 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: regional VS country MARKET ANALYSIS

FIGURE 5 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MARKET end users coverage GRID

FIGURE 10 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER and INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICs are DRIVing THE EUROPE PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 REAGENTS & CONSUMABLES segment is expected to account for the largest share of the EUROPE PROSTATE CANCER DIAGNOSTICS MARKETin 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PROSTATE CANCER DIAGNOSTICS MARKET

FIGURE 15 GERIATRIC POPULATION IN THE EUROPEAN REGION

FIGURE 16 Europe prostate cancer diagnostics market : BY product type, 2020

FIGURE 17 Europe prostate cancer diagnostics market : BY product type, 2021-2028 (USD Million)

FIGURE 18 Europe prostate cancer diagnostics market : BY product type, CAGR (2021-2028)

FIGURE 19 PROSTATE CANCER DIAGNOSTICS market : BY product type, LIFELINE CURVE

FIGURE 20 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, 2020

FIGURE 21 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE 2021-2028 (USD Million)

FIGURE 22 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, CAGR (2021-2028)

FIGURE 23 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, LIFELINE CURVE

FIGURE 24 Europe prostate cancer diagnostics market : By type, 2020

FIGURE 25 Europe prostate cancer diagnostics market : By type, 2021-2028 (USD Million)

FIGURE 26 Europe prostate cancer diagnostics market : By type, CAGR (2021-2028)

FIGURE 27 Europe prostate cancer diagnostics market : By type, LIFELINE CURVE

FIGURE 28 Europe prostate cancer diagnostics market : BY age group, 2020

FIGURE 29 Europe prostate cancer diagnostics market : BY age group, 2021-2028 (USD Million)

FIGURE 30 Europe prostate cancer diagnostics market : BY age group, CAGR (2021-2028)

FIGURE 31 Europe prostate cancer diagnostics market : BY age group, LIFELINE CURVE

FIGURE 32 Europe prostate cancer diagnostics market : BY stage, 2020

FIGURE 33 Europe prostate cancer diagnostics market : BY stage, 2021-2028 (USD Million)

FIGURE 34 Europe prostate cancer diagnostics market : BY stage, CAGR (2021-2028)

FIGURE 35 Europe prostate cancer diagnostics market : BY stage, LIFELINE CURVE

FIGURE 36 Europe prostate cancer diagnostics market : BY sample type, 2020

FIGURE 37 Europe prostate cancer diagnostics market : BY sample type, 2021-2028 (USD Million)

FIGURE 38 Europe prostate cancer diagnostics market : BY sample type, CAGR (2021-2028)

FIGURE 39 Europe prostate cancer diagnostics market : BY sample type, LIFELINE CURVE

FIGURE 40 Europe prostate cancer diagnostics market : BY end users, 2020

FIGURE 41 Europe prostate cancer diagnostics market : BY end users, 2021-2028 (USD Million)

FIGURE 42 Europe prostate cancer diagnostics market : BY end users, CAGR (2021-2028)

FIGURE 43 Europe prostate cancer diagnostics market : BY end users, LIFELINE CURVE

FIGURE 44 Europe prostate cancer diagnostics market : BY distribution channel, 2020

FIGURE 45 Europe prostate cancer diagnostics market : BY distribution channel, 2021-2028 (USD Million)

FIGURE 46 Europe prostate cancer diagnostics market : BY distribution channel, CAGR (2021-2028)

FIGURE 47 Europe prostate cancer diagnostics market : BY distribution, LIFELINE CURVE

FIGURE 48 Europe prostate cancer diagnostics market : SNAPSHOT (2020)

FIGURE 49 Europe prostate cancer diagnostics market : BY COUNTRY (2020)

FIGURE 50 Europe prostate cancer diagnostics market : BY COUNTRY (2021 & 2028)

FIGURE 51 Europe prostate cancer diagnostics market : BY COUNTRY (2020 & 2028)

FIGURE 52 Europe prostate cancer diagnostics market : BY Product type (2021-2028)

FIGURE 53 europe Prostate cancer diagnostics market: company share 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19